From the Journals

Aerosolized MMR vaccine showed good seropositivity


 

FROM VACCINE

Aerosolized MMR vaccine can be used in booster campaigns in school-age children for measles and rubella, said José Luis Díaz Ortega, MD, of the Instituto Nacional de Salud Pública, Mexico, and his associates.

However, more studies of school-age children with longer follow-up of mumps antibody persistence are needed, they said.

CDC/ Cynthia S. Goldsmith; William Bellini, Ph.D.

Measles viron

A 1-year serological follow-up study was done in 241 Mexican children aged 6-7 years who received vaccine MMR SII (Serum Institute of India) administered by aerosol or injection or MMR II (Merck Sharp & Dohme) by aerosol or injection. The children had a history of receiving MMR at age 1-2 years. The aerosolization was performed through a vibrating mesh nebulizer.

Courtesy CDC/NIP/Barbara Rice

Measles cases has reached a 20-year high in the United States, with 288 reported as of May 23.

The persistence of immunity 1 year after the booster vaccination showed 100% seropositivity for measles and rubella and 90.3%-96.6% for mumps. The differences were not statistically significant among the four groups (P = .485).

Aerosolized vaccines are not available in the United States.

Read more in the journal Vaccine (2017 Apr 28. doi: 10.1016/j.vaccine.2017.04.027).

Recommended Reading

Revaccinate HIV-infected teens with hepatitis B vaccine
MDedge Pediatrics
Preterm infants face increased pertussis risk
MDedge Pediatrics
WHO’s malaria pilot vaccine: No silver bullet, but a potential strike at malaria’s heart
MDedge Pediatrics
International travel vaccination updates
MDedge Pediatrics
Rotavirus vaccination in last decade cuts AGE hospitalization
MDedge Pediatrics
Two doses HPV vaccine are as good as three against genital warts
MDedge Pediatrics
Lower-dose aluminum hydroxide–adjuvanted polio vaccine noninferior to standard IPV
MDedge Pediatrics
Safe, effective backup for U.S. MMR vaccine exists
MDedge Pediatrics
Meningococcal B, C vaccines together lead to adequate immune response
MDedge Pediatrics
Two-dose HPV vaccine trials in teens show effective immunological responses
MDedge Pediatrics